MannKind Corporation

DB:NNFN Stock Report

Market Cap: €1.1b

MannKind Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Michael Castagna

Chief executive officer

US$9.5m

Total compensation

CEO salary percentage8.08%
CEO tenure8yrs
CEO ownership0.9%
Management average tenure2.6yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Castagna's remuneration changed compared to MannKind's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

US$30m

Dec 31 2024US$9mUS$766k

US$28m

Sep 30 2024n/an/a

US$22m

Jun 30 2024n/an/a

US$12m

Mar 31 2024n/an/a

US$8m

Dec 31 2023US$7mUS$702k

-US$12m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$4mUS$623k

-US$87m

Sep 30 2022n/an/a

-US$98m

Jun 30 2022n/an/a

-US$88m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$4mUS$598k

-US$81m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$4mUS$495k

-US$57m

Sep 30 2020n/an/a

-US$45m

Jun 30 2020n/an/a

-US$44m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$2mUS$511k

-US$52m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$61m

Mar 31 2019n/an/a

-US$71m

Dec 31 2018US$2mUS$500k

-US$87m

Compensation vs Market: Michael's total compensation ($USD9.49M) is above average for companies of similar size in the German market ($USD1.72M).

Compensation vs Earnings: Michael's compensation has increased by more than 20% in the past year.

CEO

Michael Castagna (47 yo)

8yrs
Tenure
US$9,490,628
Compensation

Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Castagna
CEO & Director8yrsUS$9.49m0.86%
€ 9.5m
Christopher Prentiss
Chief Financial Officer1.1yrsUS$3.49mno data
Lauren Sabella
Executive Vice President of Operations2.2yrsUS$2.97m0.035%
€ 386.8k
David Thomson
Executive VP23.3yrsUS$3.06m0.18%
€ 2.0m
Burkhard Blank
Executive VP of Research & Development and Chief Medical Officer2yrsUS$2.96m0.064%
€ 706.1k
Sanjay Singh
Executive Vice President of Technical Operations2.6yrsUS$1.12m0.032%
€ 355.1k
Rosabel Alinaya
VP of Investor Relations & Treasury7.8yrsUS$519.59kno data
Stuart Tross
Executive Vice President of Human Resources8.4yrsUS$2.22m0.25%
€ 2.7m
John Bedard
Senior Vice President of Worldwide Regulatory Affairs19.6yrsno datano data
Kevin Kaiserman
Senior VP & Therapeutic Area Head of Endocrine Diseases2.3yrsno datano data
Dominic Marasco
President of Endocrine Business Unitless than a yearno data0.0072%
€ 79.8k
2.6yrs
Average Tenure
57.5yo
Average Age

Experienced Management: NNFN's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Castagna
CEO & Director8yrsUS$9.49m0.86%
€ 9.5m
Ronald Consiglio
Independent Director21.6yrsUS$235.96k0.039%
€ 430.5k
Kent Kresa
Chairman Emeritusless than a yearUS$213.46k0.087%
€ 963.0k
Christine Ann Mundkur
Independent Director6.5yrsUS$220.96k0.0091%
€ 100.6k
Michael Friedman
Independent Director21.4yrsUS$210.96k0.0049%
€ 54.4k
Anthony Hooper
Independent Director5.3yrsUS$235.96k0.066%
€ 731.2k
James Shannon
Independent Chairman10yrsUS$245.96k0.0080%
€ 88.9k
Sabrina Kay
Independent Director4.4yrsUS$223.46k0.035%
€ 389.1k
Thomas Blevins
Member of Scientific Advisory Board3.8yrsno datano data
Steven Binder
Independent Directorless than a yearUS$2.25m0.20%
€ 2.2m
Jennifer Grancio
Independent Director5.2yrsUS$225.96k0.036%
€ 402.4k
Davida Kruger
Member of Scientific Advisory Board3.8yrsno datano data
5.3yrs
Average Tenure
64.5yo
Average Age

Experienced Board: NNFN's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 15:08
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MannKind Corporation is covered by 27 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas RussoBaird
Stephen V. ByrneBofA Global Research
null nullBTIG